MARKET

RLMD

RLMD

Relmada
NASDAQ

Real-time Quotes | Nasdaq Last Sale

34.89
+0.61
+1.78%
Closed 16:00 12/03 EST
OPEN
34.34
PREV CLOSE
34.28
HIGH
35.00
LOW
34.20
VOLUME
23.60K
TURNOVER
--
52 WEEK HIGH
54.00
52 WEEK LOW
23.25
MARKET CAP
566.67M
P/E (TTM)
-11.8335
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
We Think Relmada Therapeutics (NASDAQ:RLMD) Can Afford To Drive Business Growth
Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Simply Wall St. · 1d ago
Relmada Therapeutics to Participate in Upcoming Investor Conferences
, /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a clinical-stage company developing novel therapies for the treatment of central nervous system (CNS) diseases, today announced that , Chief Executive Officer of Relmada, will participate in the following upcoming virtual investor conferences:
PR Newswire - PRF · 11/17 13:30
Relmada Therapeutics to Participate in Upcoming Investor Conferences
Relmada Therapeutics, Inc. (Nasdaq: RLMD), a clinical-stage company developing novel therapies for the treatment of central nervous system (CNS) diseases, today announced that Sergio Traversa, Chief Executive Officer of Relmada, will participate in the following upcoming virtual investor conferences:
PR Newswire · 11/17 13:30
On the Trail of Better Therapeutics for Depression
, /PRNewswire/ -- Big pharma and life science companies are making big news these days. The drug-development space is seeing strong investor interest as these companies make breakthrough advancements that address vast unmet medical needs. Strategic M&A moves are adding spice to the gumbo for investors as pioneering research remains focused on providing life-changing treatments for those suffering from a myriad of disorders. One of the largest and trickiest medical disorders of mankind may be on the cusp of more effective treatment. Depression is often kept in the dark and not talked about, but it is estimated that  in experienced at least one major depressive episode in 2019 alone, while one out of every four people in the world struggle with a diagnosable mental disorder. Life sciences company is at the vanguard of new therapeutic protocols that target these disorders. Cybin is intent on developing psychedelic therapeutics along with unique delivery mechanisms that target depression as well as other psychiatric and neurological conditions. The company could benefit from two game-changing announcements made in the past few days: the company just and a groundbreaking study published in reports that in a recent study a treatment featuring psilocybin actually worked better than typical antidepressant medications. Other drug-development companies are experiencing similar milestone moments. Last month (NASDAQ: PRAX) closed on its upsized initial public offering of 11,500,000 shares of common stock, resulting in aggregate gross proceeds to Praxis of . Earlier this year, (NYSE: ABBV) completed a transformative acquisition of Allergan. Less than a year ago, (NASDAQ: AXSM) realized more than when it closed on its public offering. And this summer (NASDAQ: RLMD) uplisted to trade on the Nasdaq Global Select Market.  
PR Newswire - PRF · 11/10 13:30
Goldman Sachs Downgrades Relmada Therapeutics to Neutral, Lowers Price Target to $40
Goldman Sachs downgrades Relmada Therapeutics (NASDAQ:RLMD) from Buy to Neutral and lowers the price target from $69 to $40.
Benzinga · 10/28 12:22
Relmada Therapeutics beefs up leadership team; updates on REL-1017 program
Relmada Therapeutics ([[RLMD]] -1.4%) has expanded its leadership team with appointments of Dr. Paolo Manfredi, M.D., as acting Chief Scientific Officer and Marco Pappagallo, M.D., as acting Chief Medical Officer ((CMO)).Dr.
Seekingalpha · 10/27 13:24
Relmada Therapeutics Expands R&D Team, Appoints Paolo Manfredi, M.D., as Acting Chief Scientific Officer, Marco Pappagallo, M.D., as Acting Chief Medical Officer and Updates R&D Milestones
, /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a clinical-stage company developing novel therapies for the treatment of central nervous system (CNS) diseases, today announced the expansion of its leadership team with the appointments of Paolo Manfredi, M.D., as Acting Chief Scientific Officer and , M.D., as Acting Chief Medical Officer. The Company also provided an update of upcoming milestones for the REL-1017 program.
PR Newswire - PRF · 10/27 12:30
Relmada Therapeutics Expands R&D Team, Appoints Paolo Manfredi, M.D., as Acting Chief Scientific Officer, Marco Pappagallo, M.D., as Acting Chief Medical Officer and Updates R&D Milestones
Relmada Therapeutics, Inc. (Nasdaq: RLMD), a clinical-stage company developing novel therapies for the treatment of central nervous system (CNS) diseases, today announced the expansion of its leadership team with the appointments of Paolo Manfredi, M.D., as Acting Chief Scientific Officer and Marco Pappagallo, M.D., as Acting Chief Medical Officer. The Company also provided an update of upcoming milestones for the REL-1017 program.
PR Newswire · 10/27 12:30
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of RLMD. Analyze the recent business situations of Relmada through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 6 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average RLMD stock price target is 62.83 with a high estimate of 75.00 and a low estimate of 38.00.
EPS
Institutional Holdings
Institutions: 99
Institutional Holdings: 11.56M
% Owned: 71.16%
Shares Outstanding: 16.24M
TypeInstitutionsShares
Increased
22
333.39K
New
23
-163.86K
Decreased
19
222.71K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+2.41%
Pharmaceuticals & Medical Research
+0.49%
Key Executives
Chairman/Director
Charles Casamento
Chief Executive Officer/Director
Sergio Traversa
Chief Financial Officer
Maged Shenouda
Executive Vice President
Thomas Wessel
Senior Vice President
Marc de Somer
Chief Accounting Officer/Chief Compliance Officer
Charles Ence
Vice President
Judy Caron
Chief Scientific Officer
Paolo Manfredi
Other
Marco Pappagallo
Independent Director
John Glasspool
Independent Director
Paul Kelly
Independent Director
Eric Schmidt
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About RLMD
Relmada Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on developing treatments for central nervous system (CNS) disorders. Its product candidate includes dextromethadone (d-methadone), REL-1017, REL-1015 (LevoCap ER), REL-1028 (BuTab) and REL-1021 (MepiGel). d-methadone (dextromethadone, REL-1017) is an N-methyl-D-aspartate (NMDA) receptor antagonist. d-methadone is a new chemical entity (NCE) that is being developed for the treatment of central nervous system (CNS) diseases and other disorders. It is also being developed for the treatment of depression, ophthalmological disorders and/or other potential indications. REL-1015 (LevoCap ER) product candidate is an extended release, abuse deterrent, proprietary formulation of the opioid analgesic levorphanol. REL-1028 is a novel oral formulations of modified release buprenorphine. MepiGel is a topical dosage form of the local anesthetic mepivacaine.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Relmada Therapeutics Inc stock information, including NASDAQ:RLMD real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, RLMD stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading RLMD stock methods without spending real money on the virtual paper trading platform.